Author:
Caritis Steve N.,Venkataramanan Raman,Thom Elizabeth,Harper Margaret,Klebanoff Mark A.,Sorokin Yoram,Thorp John M.,Varner Michael W.,Wapner Ronald J.,Iams Jay D.,Carpenter Marshall W.,Grobman William A.,Mercer Brian M.,Sciscione Anthony,Rouse Dwight J.,Ramin Susan
Funder
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health
Subject
Obstetrics and Gynaecology
Reference21 articles.
1. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate;Meis;N Engl J Med,2003
2. ACOG committee opinion no 419: use of progesterone to reduce preterm birth;Obstet Gynecol,2008
3. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Guidance for industy. Exposure-response relationships–study design, data analysis, and regulatory applications. April 2013. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf. Accessed April 26, 2013.
4. Expert Working Group (Efficacy). International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). Guideline for industy. Dose-response information to support drug registration. November 1994. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073115.pdf. Accessed April 26, 2013.
5. Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor;Johnson;N Engl J Med,1975
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献